Schroder Investment Management Group
EWTX icon

Schroder Investment Management Group’s Edgewise Therapeutics EWTX Stock Holding History

Schroder Investment Management Group’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-145,286
Closed -$4.4M – 1195
2026
Q1 		$4.4M Hold
145,286
– – ﹤0.01% 803
2025
Q4 		$3.57M Sell
145,286
-5,776
-4% -$116K ﹤0.01% 807
2025
Q3 		$2.38M Hold
151,062
– – ﹤0.01% 902
2025
Q2 		$1.98M Buy
151,062
+71,911
+91% +$1.04M ﹤0.01% 909
2025
Q1 		$1.84M Sell
79,151
-13,910
-15% -$365K ﹤0.01% 920
2024
Q4 		$2.52M Buy
+93,061
New +$2.96M ﹤0.01% 892

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Schroder Investment Management Group's EWTX Position: Q2 2026 in Review

Schroder Investment Management Group sold out of Edgewise Therapeutics (EWTX) in Q2 2026, closing a stake of 145,286 shares — an estimated $4.4M sold.

Schroder Investment Management Group first reported a position in EWTX in Q4 2024 and held it in 6 quarters. The position peaked at $4.4M in Q1 2026. 223 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Schroder Investment Management Group reported no remaining Edgewise Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Schroder Investment Management Group sold 145,286 Edgewise Therapeutics shares in Q2 2026, an estimated $4.4M.
  • Schroder Investment Management Group first reported a position in Edgewise Therapeutics in Q4 2024 and held it in 6 quarters.
  • Schroder Investment Management Group's Edgewise Therapeutics position peaked at $4.4M in Q1 2026.
  • 223 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Schroder Investment Management Group's 13F filing for Q2 2026, filed 13 Aug 2026.